Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INVIGORATE 2: Reproxalap in Seasonal Allergic Conjunctivitis
NCT05234554Phase 3Completed
- Sponsor
- Aldeyra Therapeutics
- Start
- Jan 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of reproxalap in allergic conjunctivitis (AC), sponsored by Aldeyra Therapeutics. Started Jan 2022; status: completed.
02
Drugs
reproxalap
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT05234554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05234554.